Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IONIS-FXIRx: Ph II data

A double-blind, Canadian Phase II trial in 43 patients with ESRD receiving hemodialysis showed

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE